eicosapentaenoic acid ethyl ester has been researched along with Bleeding in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (33.33) | 24.3611 |
| 2020's | 2 (66.67) | 2.80 |
| Authors | Studies |
|---|---|
| Magness, JW | 1 |
| Arnwine, C | 1 |
| Lockwood, K | 1 |
| Reinert, A | 1 |
| Synnott, PG | 1 |
| McQueen, RB | 1 |
| Ollendorf, DA | 1 |
| Campbell, JD | 1 |
| Pearson, SD | 1 |
| Sheikh, O | 1 |
| Vande Hei, AG | 1 |
| Battisha, A | 1 |
| Hammad, T | 1 |
| Pham, S | 1 |
| Chilton, R | 1 |
2 reviews available for eicosapentaenoic acid ethyl ester and Bleeding
| Article | Year |
|---|---|
The Effectiveness and Value of Rivaroxaban and Icosapent Ethyl as Additive Therapies for Cardiovascular Disease.
Topics: Aspirin; Cardiovascular Diseases; Cost-Benefit Analysis; Dose-Response Relationship, Drug; Drug Cost | 2020 |
Cardiovascular, electrophysiologic, and hematologic effects of omega-3 fatty acids beyond reducing hypertriglyceridemia: as it pertains to the recently published REDUCE-IT trial.
Topics: Atrial Fibrillation; Biomarkers; Cardiovascular Diseases; Dietary Supplements; Down-Regulation; Eico | 2019 |
1 other study available for eicosapentaenoic acid ethyl ester and Bleeding
| Article | Year |
|---|---|
Add-On Therapies in Cardiovascular Disease: Reviewing ICER's Report and the Potential Effect on Payers.
Topics: Age Factors; Aspirin; Cardiovascular Diseases; Cost-Benefit Analysis; Dose-Response Relationship, Dr | 2020 |